AstraZeneca’s Oral SERD Is First To Succeed In Frontline Breast Cancer

 
• By Andrew McConaghie

A novel Phase III design using circulating DNA testing has delivered success for SERENA-6, putting it ahead of competing studies from Roche and Pfizer/Arvinas.

Astrazeneca
• Source: Shutterstock

More from Clinical Trials

More from Anticancer